Transcriptional Signature of an Altered Purine Metabolism in the Skeletal Muscle of a Huntington's Disease Mouse Model
暂无分享,去创建一个
[1] A. Wyttenbach,et al. In Vitro and in Vivo Aggregation of a Fragment of Huntingtin Protein Directly Causes Free Radical Production* , 2011, The Journal of Biological Chemistry.
[2] M. Isalan,et al. An impaired metabolism of nucleotides underpins a novel mechanism of cardiac remodeling leading to Huntington's disease related cardiomyopathy. , 2016, Biochimica et biophysica acta.
[3] I. Arinze. Facilitating understanding of the purine nucleotide cycle and the one‐carbon pool: Part I: The purine nucleotide cycle , 2005, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.
[4] E. Olson,et al. Signaling pathways in skeletal muscle remodeling. , 2006, Annual review of biochemistry.
[5] M. Isalan,et al. Changes in cardiac nucleotide metabolism in Huntington's disease , 2016, Nucleosides, nucleotides & nucleic acids.
[6] J. Marcinkowski,et al. Skeletal muscle pathology in Huntington's disease , 2014, Front. Physiol..
[7] Thomas H Gillingwater,et al. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation , 2004, The European journal of neuroscience.
[8] M. Russo,et al. Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects , 2006, Cell Death and Differentiation.
[9] Mark Turmaine,et al. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.
[10] K. Hoyt,et al. Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.
[11] S. Ayala‐Peña,et al. Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis. , 2013, Free radical biology & medicine.
[12] G. Bates,et al. Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the HdhQ150 Knock-In Mouse Model of Huntington's Disease , 2009, PloS one.
[13] C. Padovani,et al. Skeletal muscule fiber types in C57BL6J mice , 2004 .
[14] Y. Kokubo,et al. Associations of Hypertension and Its Complications with Variations in the Xanthine Dehydrogenase Gene , 2008, Hypertension Research.
[15] M. Isalan,et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice , 2012, Proceedings of the National Academy of Sciences.
[16] Erich E Wanker,et al. The hunt for huntingtin function: interaction partners tell many different stories. , 2003, Trends in biochemical sciences.
[17] G. Landwehrmeyer,et al. Update on Huntington's disease: advances in care and emerging therapeutic options. , 2015, Parkinsonism & related disorders.
[18] P. Marks,et al. SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease , 2011, PloS one.
[19] A. Hannan,et al. Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease , 2012, The Journal of physiology.
[20] N. Déglon,et al. Mitochondria in Huntington's disease. , 2010, Biochimica et biophysica acta.
[21] M. Isalan,et al. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice , 2016, Molecular Neurodegeneration.
[22] L. Zuo,et al. Redox Characterization of Functioning Skeletal Muscle , 2015, Front. Physiol..
[23] M. Isalan,et al. A shared mechanism of muscle wasting in cancer and Huntington’s disease , 2015, Clinical and Translational Medicine.
[24] S. W. Davies,et al. Formation of polyglutamine inclusions in non-CNS tissue. , 1999, Human molecular genetics.
[25] T. Morisaki,et al. Subunit composition of AMPD varies in response to changes in AMPD1 and AMPD3 gene expression in skeletal muscle. , 1996, Proceedings of the Association of American Physicians.
[26] K. Myburgh,et al. Skeletal muscle wasting with disuse atrophy is multi-dimensional: the response and interaction of myonuclei, satellite cells and signaling pathways , 2014, Front. Physiol..
[27] L. Greensmith,et al. HDAC4-Myogenin Axis As an Important Marker of HD-Related Skeletal Muscle Atrophy , 2015, PLoS genetics.
[28] G. Bates,et al. Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease , 2014, PLoS genetics.
[29] M. Mielcarek. Huntington's disease is a multi-system disorder , 2015, Rare diseases.
[30] L. Fairbanks,et al. Purine Nucleoside Phosphorylase Deficiency: A Mutation Update , 2011, Nucleosides, nucleotides & nucleic acids.
[31] Erich E. Wanker,et al. HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration , 2013, PLoS biology.
[32] Gilles J Guillemin,et al. The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review , 2016, Oxidative medicine and cellular longevity.
[33] A. Krook,et al. Regulation of Skeletal Muscle Physiology and Metabolism by Peroxisome Proliferator-Activated Receptor δ , 2009, Pharmacological Reviews.
[34] B. Landwehrmeyer,et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[35] W. Roberts,et al. Characterization of reactive oxygen species in diaphragm , 2015, Acta physiologica.
[36] S. Folstein,et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues , 1993, Neuron.
[37] M. Vinciguerra,et al. Regulation of muscle atrophy in aging and disease. , 2010, Advances in experimental medicine and biology.
[38] Carlo Reggiani,et al. Fiber types in mammalian skeletal muscles. , 2011, Physiological reviews.
[39] L. Zuo,et al. Redox Roles of Reactive Oxygen Species in Cardiovascular Diseases , 2015, International journal of molecular sciences.